



The -Omics Revolution Meets Microbiology and Infectious Diseases



James Versalovic, M.D., Ph.D.
Director, Division of Molecular Pathology
Director, Microbiology Laboratories
Department of Pathology
Texas Children's Hospital

Associate Professor of Pathology, Pediatrics, Molecular Virology & Microbiology, Molecular and Human Genetics Baylor College of Medicine

DISCLOSURE


- Receives Royalties from Biomerieux Inc. for DiversiLab
- Past Research Support from Roche Diagnostics

Texas Children's Hospital Molecular Microbiology Team



From Microbial Genomics to Diagnostic Microbiology: BENCH TO BENCH

POSITIVE CULTURES




Highlights: A Summary

- Pathogen Identification
- Drug-Resistant Pathogens
 - Strain Tracking
- Enteric Pathogens
 - Gastroenteritis
 - Diagnosis of Clostridium difficile Infections
- Respiratory Pathogens
 - Challenging the single virus and single bacterial species paradigm

Difficult-to-Identify Pathogens

- Organisms requiring DNA sequencing for identification at Texas Children's Hospital
- Cystic fibrosis
 - Burkholderia cepacia complex
 - Atypical Pseudomonas aeruginosa
- Microbacterium spp.
 - Considered as blood culture contaminant
- Rothia mucilaginosa
 - Neutropenic children with hematologic malignancies

Biochemical – Molecular Identification Molecular Microbiology Work Flow



Approximately 20-30 Vitek workups per day in the TCH Microbiology Laboratory.

Between December 2003 and July 2006, a total of 414 cultured isolates (312 children) were submitted and processed for DNA pyrosequencing.

Approximately 90% (n=372) of isolates were identified and reported by DNA pyrosequencing.


Luna RA et al. (2007) J Clin Microbiol 45:2985-2992.


78 different genera : 51% to species level

Rothia mucilaginosa Clinical Case

- 20 year-old male with relapsed chronic myelogenous leukemia (CML)
- Status post-bone marrow transplantation (x3) and failed engraftment
- Developed meningitis and encephalopathy unresponsive to antibiotics
- Severe diffuse cerebral edema
- Diffuse ependymitis

Direct Diagnosis of Rothia mucilaginosa Infection







- Direct PCR
 amplification from
 cerebral meninges at
 autopsy
- DNA Pyrosequencing identified Rothia mucilaginosa

Identification of *Pseudomonas* aeruginosa in CF Cultures

- Sputum samples collected from patients with cystic fibrosis at each quarterly visit.
- P. aeruginosa identified through a combination of culture on selective media and biochemical testing.







Identification of *Pseudomonas* aeruginosa by Pyrosequencing

- Some Pseudomonas aeruginosa isolates from patients with cystic fibrosis are difficult to identify by conventional microbiology methods due to their phenotypic diversity.
- Many *Pseudomonas* isolates from respiratory cultures of patients were submitted for pyrosequencing bacterial identification.

Pyrosequencing Identification of Pseudomonas aeruginosa




Bacterial PSQ ID Volumes



Pyrosequencing Identification of Pseudomonas aeruginosa

• For more than 3 years, 47 isolates from sputum and BAL samples were identified as *Pseudomonas aeruginosa*.



DNA Pyrosequencing Report

PYROSEQUENCING ID

Cellulomonas denverensis (Culture Acc XXXXX) was identified by DNA pyrosequencing.

This test was developed and its performance characteristics determined by Texas Children's Hospital. It has not been cleared or approved by the U.S. FDA.

Multi-Drug Resistant Pseudomonas aeruginosa


- Resistant to all antibiotics in 2 or more groups below
 - Resistant to all <u>aminoglycosides</u> tested
 - Tobramycin
 - Gentamicin
 - Amikacin
 - Resistant to all quinolones tested
 - Ciprofloxacin
 - Resistant to all <u>beta lactams</u> tested
 - Ceftazidime
 - Meropenem
 - Timentin
 - Piperacillin
 - Ticarcillin
 - Aztreonam

Molecular Typing of *Pseudomonas* aeruginosa in Cystic Fibrosis

- Several studies utilizing molecular typing of Pseudomonas aeruginosa in cystic fibrosis in late 1990s and 2000s.
- Methodology included mostly PFGE and RAPD, no study used rep-PCR.
- No study has specifically focused on MRPA.
- However, in 2 studies, the dominant clone was found to be MRPA.
 - Jones AM, et al. Lancet. 2001 Aug 18;358(9281):557-8.
 - Armstrong D, et al. J Clin Microbiol. 2003 May;41(5):2266-7.

MOLECULAR EPIDEMIOLOGY – DNA FINGERPRINTING

PULSED-FIELD GEL ELECTROPHORESIS




REP-PCR




DNA SEQUENCING

Which bacterial clone or strain is responsible for clusters of hospital-associated infections?


One or many clones?



Molecular Typing at TCH




Multi-Drug Resistant P. aeruginosa Clusters by Year



Collaboration with Peter Hiatt, M.D. and Jeffrey Starke, M.D. at Texas Children's Hospital, Houston, TX

July 2008 Scatterplot



DiversiLab Report

Newly submitted *Enterobacter cloacae* isolates XXXX and XXXXX are indistinguishable by rep-PCR and may represent the same clone. These data suggest a genetic relationship may exist among these isolates. A common point source for these bacterial isolates may exist. Newly submitted isolate XXXXX is similar to isolates XXXX and XXXXXX.

Newly submitted isolates XXXXX is clearly distinguishable from all other isolates in this sample set by rep-PCR. Based on these data, there is no evidence of a genetic relationship involving this isolate. Stated differently, the data do <u>not</u> suggest horizontal transmission or a common point source for this bacterial isolate.

When compared to the Ukent *Enterobacter cloacae* Library, newly submitted isolates XXXXX, XXXX, and XXXXX are similar to previously submitted isolate XXXXXX. Newly submitted isolate XXXXX is clearly distinguishable from from all isolates in the library.

Molecular Typing Redefined Infection Control in CF Center

- Dominant MRPA clone was focus of infection control efforts
 - Facile transmission between patients
- Children were tracked, treated promptly, and placed in contact isolation at TCH
- Parents were counseled; multiple interventions
- As of July 2008, only 2 new patients were identified with the dominant clone in approximately 18 months.
 - MRPA is under control locally

Challenges in Diagnosing Pediatric Infections of the Digestive System

- Variety of Etiologies to Consider
 - Bacterial, Viral, Parasitic
 - New, Re-Emerging, or Under-Appreciated Agents
- Colonization versus Infection
 - Human Microbiota and Microbiome
 - Bacteria and Viruses
 - Example of C. difficile Colonization in Infants
- Limitations of Current Stool-Based Strategies
 - Bacteriologic Culture
 - Antigen Detection

Clostridium difficile





Gram stain


Culture on CCFA Agar

Originally labeled "Bacillus difficilis" in 1930s – the "difficult one"

Summary of C. difficile PCR Validation

- 22 true positive samples based on stool anaerobic culture / PCR / immunoassay
 - 19 positive samples or 86% sensitivity for direct real-time PCR
 - 9 positive samples or 37.5% sensitivity for direct toxin testing
 - Low sensitivity may reveal limitations with pediatric samples
- 122 true negative samples based on culture/ PCR / Immunoassay
 - 117 negative samples or 96% specificity by direct real-time PCR
 - 122 negative samples or 100% specificity by direct toxin testing
- Association for Molecular Pathology meeting in Orlando (November 2006)
 - S. M. Paule et al. J Mol Diagnostics 2006;8:653. (Northwestern)
 - Real-time PCR (tcdB only)
 - 77% sensitivity and 99% specificity when compared to toxigenic culture
 - Excellent correlation between toxin gene detection and toxigenic culture
 - "... real-time PCR provides the best combination of speed and accuracy."

CDF Yearly Volumes & Positivity Rates



C. difficile PCR Report

C DIFFICILE TOX PCR


Negative for toxigenic Clostridium difficile.

Note: Published data indicate that up to 65% of infants may have asymptomatic colonization of toxigenic C. difficile due to the immature nature of the digestive tract in infants up to 1 year of age. Other causes of diarrhea, particularly enteric viruses, should be considered in this age group.


Methodology: Bacterial DNA, if present, was extracted from a stool specimen. Real time PCR with primers and probes specific for *Clostridium difficile* toxin producing genes tcdA and tcdB was performed. This test was developed and its performance characteristics determined by Texas Children's Hospital. It has not been cleared or approved by the U.S. FDA.

Challenge: Diagnosis of Respiratory Tract Infections


- Continually expanding repertoire of respiratory viruses
- Complexity of bacterial colonization in ventilatorassociated infections



BACTERIAL/FUNGAL IDENTIFICATION




DNA SEQUENCING
Today




REAL-TIME PCR

Today



PYROSEQUENCING


Today




ARRAYS AND MICROARRAYS

Have arrived

Liquid Bead Arrays







Proteins



Oligonucleotides







Luminex-100

High-Throughput, Sensitive, and Accurate Multiplex PCR-Microsphere Flow Cytometry System for Large-Scale Comprehensive Detection of Respiratory Viruses[∇]†

Wai-Ming Lee,^{1*} Kris Grindle,¹ Tressa Pappas,¹ David J. Marshall,³ Michael J. Moser,³ Edward L. Beaty,³ Peter A. Shult,² James R. Prudent,³ and James E. Gern¹

Department of Pediatrics and Medicine¹ and Wisconsin State Laboratory of Hygiene,² University of Wisconsin, Madison, Wisconsin, and EraGen Biosciences Incorporated, Madison, Wisconsin³

Received 13 December 2006/Returned for modification 5 March 2007/Accepted 20 April 2007

Respiratory viral panel (Luminex) was FDA-approved on Jan. 3, 2008

JOURNAL OF CLINICAL MICROBIOLOGY, Sept. 2007, p. 2965–2970 0095-1137/07/\$08.00+0 doi:10.1128/JCM.02436-06 Copyright © 2007, American Society for Microbiology. All Rights Reserved.

Vol. 45, No. 9

Development of a Respiratory Virus Panel Test for Detection of Twenty Human Respiratory Viruses by Use of Multiplex PCR and a Fluid Microbead-Based Assay

J. Mahony, 1* S. Chong, 1 F. Merante, 2 S. Yaghoubian, 2 T. Sinha, 1 C. Lisle, 2 and R. Janeczko 2


Department of Pathology and Molecular Medicine, McMaster University, and St. Joseph's Healthcare, Hamilton, Ontario, Canada, and TmBioscience Corporation, Toronto, Ontario, Canada²

Received 4 December 2006/Returned for modification 4 April 2007/Accepted 17 June 2007

Array-Based Respiratory Virus Detection

- Liquid bead arrays by Respiratory Multi-code-PLx Assay (RMA) and microsphere flow cytometery (Luminex)
- RMA detected respiratory viruses in 71.8% versus 23.3% of clinical specimens by DFA and viral culture
- Nasal wash samples from 5 year-old children

Lee W-M et al. (2007) J Clin Microbiol 45:2626-2634



Target in each well

RVP Report Text from ViraCor -1

RESP VIRAL PANEL

NASAL WASH Results as Follows:

Metapneumovirus	Not Detected
Rhinovirus	POSITIVE
Influenza A	Not Detected
Influenza A subtype H1	Not Detected
Influenza A subtype H3	Not Detected
Influenza B	Not Detected
RSV A	Not Detected
RSV B	Not Detected
Parainfluenza 1	Not Detected
Parainfluenza 2	Not Detected
Parainfluenza 3	Not Detected
Adenovirus	Not Detected

REFERENCE VALUE FOR ALL ANALYTES: Not Detected.

Respiratory Virus Panel Report (cont.)

For in vitro diagnostic use. Respiratory Viral Panel is a product of Luminex Corporation performed by XXXX, a CLIA certified laboratory.

The performance characteristics for this specimen are unknown. This specimen type has not been cleared by the FDA. Results should be used in conjunction with clinical findings.


For influenza A specimens reported as "Not Detected" for both the matrix gene target and the hemagglutinin gene target, the FDA cleared RVP package insert states the following: "It is recommended that specimens found to be negative for influenza A matrix gene target and influenza A hemagglutinin gene target in a respiratory viral panel

nucleic acid detection assay be confirmed by cell culture. Negative results do not preclude respiratory virus infection and should not be used as the sole basis for diagnosis, treatment, or other management decisions."

TEST PERFORMED BY XXXXX


Viracor

DNA Microarrays for Pathogen Detection in a Microbial World



The ViroChip

- Microarray-based viral detection
 - 70mer spotted arrays
- ViroChip microarray recognizes greater than 140 viruses
- Human rhinovirus detected post-infection (panel A)
 - Nasal lavage
- Human rhinovirus detection in natural colds (panel B)
 - Nasal lavage
- Human parainfluenza virus 1 detected (panel C)
 - Nasal lavage




Loss of Bacterial Diversity during Antibiotic Treatment of Intubated Patients Colonized with *Pseudomonas aeruginosa*[∇]

J. L. Flanagan, † E. L. Brodie, † L. Weng, S. V. Lynch, O. Garcia, R. Brown, P. Hugenholtz, T. Z. DeSantis, G. L. Andersen, J. P. Wiener-Kronish, and J. Bristow **

Department of Anesthesia and Perioperative Care, University of California, San Francisco, California 94143¹; Earth Sciences Division, Lawrence Berkeley National Laboratory, 1 Cyclotron Road, Berkeley, California 94720²; and DOE Joint Genome Institute, 2800 Mitchell Drive, Bldg. 400-404, Walnut Creek, California 94598³


Received 25 October 2006/Returned for modification 8 January 2007/Accepted 26 March 2007

- PhyloChip high-density oligonucleotide microarray for bacterial detection
- More than 8,000 taxa / chip
 - At least 11 probes per taxon
- 16S rRNA gene sequencing detected reduction from 16.2 to 5.6 (mean number of) bacterial species with antibiotic therapy




- Bacterial PhyloChip studies in human endotracheal aspirates
 - •intubated ICU patients
- •Sampling at beginning of parenteral antibiotic versus 4-10 days of therapy
- •Loss of bacterial diversity was correlated with ventilator-associated pneumonia during antibiotic therapy


Flanagan JL et al. (2007) J Clin Microbiol 45:1954-1962.



From Microbial Genomics to Diagnostic Microbiology: BENCH TO BENCH

POSITIVE CULTURES







The Human Microbiome Project: Indigenous Microbiota and Microbiome

P Eckburg et al. *Science* (2005) 308:1635-1638


>60% novel bacteria

>80% nonculturable bacteria





Mixed Microbial Communities



Human Colon 800-1000 species

Firmicutes

Bacteroidetes

Firmicutes include Lactobacillus spp.


PJ Turnbaugh et al. *Nature* (2007) 449:804-810.


S. Macfarlane et al. *Appl Environ Microbiol* (2005) 71:7483-7492.

Is it Microbial Composition or Functional Genomics?

A core gut microbiome in obese and lean twins

Peter J. Turnbaugh¹, Micah Hamady³, Tanya Yatsunenko¹, Brandi L. Cantarel⁵, Alexis Duncan², Ruth E. Ley¹, Mitchell L. Sogin⁶, William J. Jones⁷, Bruce A. Roe⁸, Jason P. Affourtit⁹, Michael Egholm⁹, Bernard Henrissat⁵, Andrew C. Heath², Rob Knight⁴ & Jeffrey I. Gordon¹





Turnbaugh et al. 2009;457:480-485.

Highlights: A Summary

- Bacterial and Fungal Pathogen Identification
- Drug-Resistant Pathogens
 - Strain Tracking
- Enteric Pathogens
 - Gastroenteritis
 - Diagnosis of Clostridium difficile Infections
- Respiratory Tract Infections, Viruses and Bacterial Communities
 - Respiratory Virus Panels and ViroChip
 - Challenging the single species paradigm

